PreS1 epitope recognition in nerborns after vaccination with the third-generation Sci-B-Vac™ vaccine and their relation to the antibody response to hepatitis B surface antigen - VBI Vaccines

PreS1 epitope recognition in nerborns after vaccination with the third-generation Sci-B-Vac™ vaccine and their relation to the antibody response to hepatitis B surface antigen

January 1, 2009 |

PreS1 epitope recognition in nerborns after vaccination with the third-generation Sci-B-Vac™ vaccine and their relation to the antibody response to hepatitis B surface antigen
Virology Journal
January 2009

View More

March 13, 2023

VBI Vaccines Reports Full Year 2022 Financial Results

February 23, 2023

VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat

February 15, 2023

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

December 8, 2022

VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI